Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.

NACE has collaborated with 17 Australian general practices and allergy clinics to launch the ARISE trial for young people with hay fever.

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

Results from the trial showed that patients started with an average HbA1c level of 8.1% and dropped to 7.2%. Credit: Shutterstock / Rost9. Individuals with type 1 diabetes (T1D) have demonstrated ...

The Knight Family DIAN-TU platform trial was initiated in 2012. Image credit: Shutterstock / Orawan Pattarawimonchai. Roche’s discontinued Alzheimer’s disease drug has shown signs that it could ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Evinova has partnered with QLHC to incorporate its RPM solution into the I-SPY 2.2 trial of various breast cancer treatments.

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

The FDA has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the Phase III CATT1 trial for T1D.